| Ytd | 29.82% | |
| 1y | 14.73% |
| Open | 1.48 | Prev Close | 1.48 | Low | 1.48 | High | 1.48 | Mkt Cap | 60.83M |
| Vol | 0.00 | Avg Vol | 1.28M | EPS | -1.66 | P/E | -0.89 | Forward P/E | -0.61 |
| Beta | 1.13 | Short Ratio | 1.69 | Inst. Own | 59.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.33 | 200-d Avg | 1.03 | 1yr Est | 0.00 |
ACHL News
- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will b
LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced t
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have p
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as o
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA canc
Research collaboration combines Achilles' best-in-class AI-driven, tumor-targeting technology with A
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Compan
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and me
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and me
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evalua
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translatio
- Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Comp
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed com
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Ph
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared
On Thursday, 241 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.